BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 4017416)

  • 1. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
    Straehl P; Galeazzi RL
    Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous isosorbide-dinitrate.
    Platzer R; Reutemann G; Galeazzi RL
    J Pharmacokinet Biopharm; 1982 Dec; 10(6):575-86. PubMed ID: 7182455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.
    Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G
    Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.
    Morrison RA; Wiegand UW; Jähnchen E; Höhmann D; Bechtold H; Meinertz T; Fung HL
    Clin Pharmacol Ther; 1983 Jun; 33(6):747-56. PubMed ID: 6851405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
    Laufen H; Aumann M; Leitold M
    Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
    Rietbrock N; Knoll J; Merz PG; Menke G
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
    Schaumann W
    Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
    Fung HL
    Am Heart J; 1985 Jul; 110(1 Pt 2):213-6. PubMed ID: 4013997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
    Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R
    Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.
    Abshagen U; Betzien G; Endele R; Kaufmann B
    Eur J Clin Pharmacol; 1981; 20(4):269-75. PubMed ID: 7308280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
    Keller-Stanislawski B; Marschner JP; Rietbrock N
    Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.
    Laufen H; Leitold M
    Arzneimittelforschung; 1992 Jul; 42(7):931-5. PubMed ID: 1418058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
    Menke G; Schnellhammer R; Rietbrock N
    Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
    Morrison RA; Fung HL
    J Pharmacol Exp Ther; 1984 Oct; 231(1):124-30. PubMed ID: 6491969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.
    Santoni Y; Iliadis A; Cano JP; Luccioni R; Frances Y
    J Pharmacokinet Biopharm; 1986 Feb; 14(1):1-17. PubMed ID: 3746630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
    Assinder DF; Chasseaud LF; Taylor T
    J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.
    Vogt D; Trenk D; Bonn R; Jähnchen E
    Eur J Clin Pharmacol; 1994; 46(4):319-24. PubMed ID: 7957516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.